<DOC>
	<DOCNO>NCT00185250</DOCNO>
	<brief_summary>Chronic viral cardiomyopathy disease cardiac muscle attack virus may result reduction output heart ( pump function ) thereby cause complaint chest pain , shortness breath palpitation . Betaferon ( interferon beta-1b ) market treatment Multiple Sclerosis already , , proven whether also effective patient chronic viral myocardial disease . This study conduct examine efficacy safety Betaferon patient disease . The aim treatment eliminate virus heart heart function clinical status gradually improve .</brief_summary>
	<brief_title>Betaferon/ Betaseron ( Interferon Beta-1b ) Patients With Chronic Viral Cardiomyopathy</brief_title>
	<detailed_description>The study previously post Schering AG , Germany . Schering AG , Germany rename Bayer Schering Pharma AG , Germany . Bayer Schering Pharma AG , Germany sponsor trial .</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1b</mesh_term>
	<criteria>Unexplained heart evidence Adeno , Entero and/or Parvoviruses must identify directly heart tissue Being chronic ( least 6 month onset clinical symptom ) stable phase disease Impaired cardiac function Severe ( decompensated ) acute heart failure . Any disease could better explain patient 's clinical symptom Any severe and/or malignant disease . Suffering convulsion , depression suicidal idea judge physician Serious viral bacterial infection last week Pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>Cardiomyopathy</keyword>
	<keyword>idiopathic chronic heart failure</keyword>
	<keyword>Adenovirus</keyword>
	<keyword>Enterovirus</keyword>
	<keyword>Parvovirus</keyword>
</DOC>